• Home
  •  / Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

OverviewSuggest Edit

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

TypePublic
Founded2010
HQNovato, CA, USMap
Websiteultragenyx.com
Employee Ratings4.3More
Overall CultureBMore
View Jobs (123)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)740(+22%)
Job Openings123
Revenue (FY, 2020)$271 M(+162%)
Share Price (May 2021)$106.4(-1%)
Cybersecurity ratingCMore

Key People/Management at Ultragenyx Pharmaceutical

Emil D. Kakkis

Emil D. Kakkis

Chief Executive Officer and President, Director
Daniel G. Welch

Daniel G. Welch

Chairman
Camille Bedrosian

Camille Bedrosian

Chief Medical Officer and Executive Vice President
Erik Harris

Erik Harris

Chief Commercial Officer and Executive Vice President
Dennis Huang

Dennis Huang

Chief Technical Operations Officer and Executive Vice President
Thomas Kassberg

Thomas Kassberg

Chief Business Officer and Executive Vice President
Show more

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, CA, US (HQ)
60 Leveroni Ct
Show all (1)

Ultragenyx Pharmaceutical Financials and Metrics

Ultragenyx Pharmaceutical Revenue

Ultragenyx Pharmaceutical's revenue was reported to be $271.03 m in FY, 2020
USD

Revenue (Q1, 2021)

99.4m

Net income (Q1, 2021)

(136.1m)

EBIT (Q1, 2021)

(106.6m)

Market capitalization (12-May-2021)

7.2b

Closing stock price (12-May-2021)

106.4

Cash (31-Mar-2021)

383.8m
Ultragenyx Pharmaceutical's current market capitalization is $7.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

133.0k2.6m51.5m103.7m271.0m

Cost of goods sold

1.0k1.1m

Gross profit

2.6m50.3m

Gross profit Margin, %

100%98%
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

93.0k149.0k17.0k111.0k198.0k10.7m12.8m11.8m18.2m24.1m25.8m36.3m61.7m81.5m99.4m

Cost of goods sold

225.0k141.0k273.0k452.0k766.0k

Gross profit

10.5m12.7m11.5m17.7m23.4m

Gross profit Margin, %

98%99%98%98%97%
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

24.3m93.6m161.1m100.5m113.4m433.6m713.5m

Accounts Receivable

5.2m12.7m32.8m23.1m

Prepaid Expenses

28.7m42.9m51.4m57.6m

Inventories

5.9m13.1m20.1m757.0k7.1m11.5m13.0m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

55.4m17.5m53.4m178.0m52.4m166.7m70.8m55.1m142.3m159.5m90.8m60.4m226.7m110.9m83.0m269.7m131.3m122.6m298.2m335.6m197.5m383.8m

Accounts Receivable

3.7m17.4m9.2m15.6m20.9m23.1m29.3m14.9m27.8m25.0m

Prepaid Expenses

4.2m4.9m5.5m6.9m9.4m12.3m17.1m17.8m18.9m19.2m19.7m19.4m34.0m36.8m49.7m45.0m46.6m49.2m64.8m58.2m64.3m68.0m

Inventories

2.1m3.3m5.6m10.9m13.6m14.1m11.4m11.1m14.5m12.5m
show all
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(59.8m)(145.6m)(245.9m)(302.1m)(197.6m)(402.7m)(186.6m)

Depreciation and Amortization

684.0k1.4m3.4m5.8m19.5m8.5m12.3m

Inventories

(4.1m)(7.1m)(7.1m)(5.3m)(4.5m)(1.3m)

Accounts Payable

3.2m(2.0m)2.5m3.5m3.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(13.6m)(27.2m)(43.1m)(21.4m)(51.2m)(90.4m)(52.8m)(109.7m)(174.6m)(68.3m)(141.2m)(220.4m)30.3m(22.5m)(109.8m)(96.8m)(195.9m)(308.9m)(119.0m)(93.7m)(162.6m)(136.1m)

Depreciation and Amortization

117.0k278.0k472.0k201.0k463.0k904.0k544.0k1.2m2.3m1.2m2.2m3.3m6.2m12.2m16.6m2.1m4.2m6.4m2.9m6.0m9.1m3.4m

Inventories

(3.6m)(6.0m)(6.6m)149.0k521.0k(2.6m)474.0k

Accounts Payable

2.1m2.0m2.7m437.0k4.8m(544.0k)2.6m2.8m3.8m3.0m6.4m3.9m(1.3m)1.4m(593.0k)(151.0k)(3.6m)266.0k
show all
USDQ1, 2014

Financial Leverage

1 x
Show all financial metrics

Ultragenyx Pharmaceutical Cybersecurity Score

Cybersecurity ratingPremium dataset

C

73/100

Learn more about our premium products
SecurityScorecard logo

Ultragenyx Pharmaceutical Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Ultragenyx Pharmaceutical Online and Social Media Presence

Ultragenyx Pharmaceutical's Trends

Embed Graph

Ultragenyx Pharmaceutical Company Culture

  • Overall Culture

    B

    80/100

  • CEO Rating

    A+

    98/100

  • Compensation

    C+

    72/100

  • Diversity

    C+

    72/100

Learn more on Comparably

Ultragenyx Pharmaceutical News and Updates

January 15, 2020

Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart?

NEW YORK, Jan. 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BAC, NIO, RARE, TLRY, and WMT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
November 19, 2019

Why Ultragenyx Pharmaceutical Stock Has Dropped 40% In The Last Quarter

Ultragenyx Pharmaceuticals (NASDAQ: RARE), a biopharmaceutical company focused on serious rare and ultra-rare genetic diseases, has seen its stock price decline by close to 40% over the last 3 months. The decline could be due to the fact that the company posted wider than expected losses...
May 07, 2018

Ultragenyx Pharmaceutical's (RARE) CEO Emil Kakkis on Q1 2018 Results - Earnings Call Transcript

Ultragenyx Pharmaceutical Blogs

May 10, 2021

Ultragenyx to Present at Bank of America Securities Healthcare Conference

Ultragenyx to Present at Bank of America Securities Healthcare Conference Content Import Mon, 05/10/2021 - 16:01 Ultragenyx to Present at Bank of America Securities Healthcare Conference May 10, 2021 This release is a backfill from a News Wire …
May 04, 2021

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update

Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update san.mai@intrado.com Tue, 05/04/2021 - 16:01 Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update May 4, 2021 This release is a backfill from a News Wire …
April 28, 2021

Ultragenyx to Present at Truist Securities Life Sciences Summit

NOVATO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will
February 11, 2021

Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update

2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million 2021 Crysvita 1 revenue in Ultragenyx territories guidance of $180 million to $190 million reaffirmed Strong Dojolvi launch continues with approximately 130 patients on reimbursed commercial therapy  in
December 17, 2020

Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx’s existing bone franchise Ultragenyx leads and funds development to approval; Mereo retains commercial rights in Europe, Ultragenyx commercializes in US and in rest of world Mereo receives $50
December 09, 2020

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease

Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease Content Import Wed, 12/09/2020 - 16:05 Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease Dec 9, 2020 This release is a backfill…
Show more

 Ultragenyx Pharmaceutical Frequently Asked Questions

  • When was Ultragenyx Pharmaceutical founded?

    Ultragenyx Pharmaceutical was founded in 2010.

  • Who are Ultragenyx Pharmaceutical key executives?

    Ultragenyx Pharmaceutical's key executives are Emil D. Kakkis, Daniel G. Welch and Camille Bedrosian.

  • How many employees does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 740 employees.

  • What is Ultragenyx Pharmaceutical revenue?

    Latest Ultragenyx Pharmaceutical annual revenue is $271 m.

  • What is Ultragenyx Pharmaceutical revenue per employee?

    Latest Ultragenyx Pharmaceutical revenue per employee is $366.3 k.

  • Who are Ultragenyx Pharmaceutical competitors?

    Competitors of Ultragenyx Pharmaceutical include Ionis Pharmaceuticals, Modis Therapeutics and Omega Therapeutics.

  • Where is Ultragenyx Pharmaceutical headquarters?

    Ultragenyx Pharmaceutical headquarters is located at 60 Leveroni Ct, Novato.

  • Where are Ultragenyx Pharmaceutical offices?

    Ultragenyx Pharmaceutical has an office in Novato.

  • How many offices does Ultragenyx Pharmaceutical have?

    Ultragenyx Pharmaceutical has 1 office.